Rznomics is joining Lilly Gateway Labs (LGL) in San Diego. The company is a clinical-stage biopharmaceutical firm based in South Korea focused on developing RNA-based gene therapies.
Lilly Gateway Labs is an innovation hub designed to help biotechnology companies advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and R&D capabilities.
Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for the company’s lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the U.S.
“Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics’ proprietary RNA platform,” said Seong-Wook Lee, CEO of Rznomics. “We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem.”
